View Cart  

FDA Expands Lilly’s Altima Use to Single Agent Maintenance Therapy

A A
The FDA has approved Eli Lilly’s Alimta for use as a single agent for continuous maintenance treatment of nonsquamous non-small cell lung cancer (NS NSCLC) based on new clinical data.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00